{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T21:41:54Z","timestamp":1777671714637,"version":"3.51.4"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jad.2023.03.068","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:18:49Z","timestamp":1679444329000},"page":"105-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Real-world characteristics of European patients receiving SNRIs as first-line treatment for major depressive disorder"],"prefix":"10.1016","volume":"332","author":[{"given":"Lucie","family":"Bartova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gernot","family":"Fugger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Dold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Kautzky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Zanardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Albani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Weidenauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Rujescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Souery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Mendlewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Zohar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Serretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siegfried","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.jad.2023.03.068_bb0005","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/13651500600637056","article-title":"Serotonin noradrenaline reuptake inhibitors: a new generation of treatment for anxiety disorders","volume":"10","author":"Baldwin","year":"2006","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.jad.2023.03.068_bb0010","first-page":"1","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part I: anxiety disorders","author":"Bandelow","year":"2022","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2023.03.068_bb0015","first-page":"1","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part II: OCD and PTSD","author":"Bandelow","year":"2022","journal-title":"World J. Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2023.03.068_bb0020","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/YIC.0000000000000078","article-title":"Efficacy of treatments for anxiety disorders: a meta-analysis","volume":"30","author":"Bandelow","year":"2015","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.jad.2023.03.068_bb0025","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00406-021-01324-1","article-title":"The German guidelines for the treatment of anxiety disorders: first revision","volume":"272","author":"Bandelow","year":"2022","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"6","key":"10.1016\/j.jad.2023.03.068_bb0030","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/15622975.2019.1635270","article-title":"Results of the European Group for the study of resistant depression (GSRD) - basis for further research and clinical practice","volume":"20","author":"Bartova","year":"2019","journal-title":"World J. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2023.03.068_bb0035","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00406-022-01390-z","article-title":"Beneficial effects of Silexan on cooccurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited","volume":"273","author":"Bartova","year":"2023","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2023.03.068_bb0040","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jpsychires.2021.06.028","article-title":"Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder - evidence from the European Group for the Study of resistant depression","volume":"141","author":"Bartova","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2023.03.068_bb0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jpsychires.2015.02.025","article-title":"Reduced default mode network suppression during a working memory task in remitted major depression","volume":"64","author":"Bartova","year":"2015","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.jad.2023.03.068_bb0050","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.eurpsy.2007.11.001","article-title":"Prescribing patterns of antidepressants in Europe: results from the factors influencing depression endpoints research (FINDER) study","volume":"23","author":"Bauer","year":"2008","journal-title":"Eur. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2023.03.068_bb0055","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/13651501.2017.1306082","article-title":"Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines","volume":"21","author":"Bauer","year":"2017","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.jad.2023.03.068_bb0060","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jad.2017.12.079","article-title":"What do the genetic association data say about the high risk of suicide in people with depression? A novel network-based approach to find common molecular basis for depression and suicidal behavior and related therapeutic targets","volume":"229","author":"Bozorgmehr","year":"2018","journal-title":"J. Affect. Disord."},{"issue":"8","key":"10.1016\/j.jad.2023.03.068_bb0065","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1177\/0269881113494937","article-title":"Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials","volume":"27","author":"Bradley","year":"2013","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.jad.2023.03.068_bb0070","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/YIC.0000000000000290","article-title":"OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females","volume":"35","author":"Brin","year":"2020","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.jad.2023.03.068_bb0075","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0924-977X(02)00057-3","article-title":"The role of noradrenaline and selective noradrenaline reuptake inhibition in depression","volume":"12","author":"Brunello","year":"2002","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.jad.2023.03.068_bb0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/YIC.0000000000000386","article-title":"Antidepressant efficacy is correlated with plasma levels: mega-analysis and further evidence","volume":"37","author":"Cellini","year":"2022","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"10128","key":"10.1016\/j.jad.2023.03.068_bb0085","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jad.2023.03.068_bb0090","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1755-5949.2010.00217.x","article-title":"The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects","volume":"17","author":"Dell'Osso","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.jad.2023.03.068_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110285","article-title":"Melancholic features in major depression - a european multicenter study","volume":"110","author":"Dold","year":"2021","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2023.03.068_bb0100","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/ijnp\/pyy009","article-title":"Major depression and the degree of suicidality: results of the european Group for the Study of resistant depression (GSRD)","volume":"2","author":"Dold","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"7","key":"10.1016\/j.jad.2023.03.068_bb0105","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/ijnp\/pyaa034","article-title":"Treatment response of add-on esketamine nasal spray in resistant major depression in relation to add-on second-generation antipsychotic treatment","volume":"23","author":"Dold","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2023.03.068_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2017.02.020","article-title":"Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a european multicenter study","volume":"91","author":"Dold","year":"2017","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.jad.2023.03.068_bb0115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/13651501.2016.1248852","article-title":"Evidence-based pharmacotherapy of treatment-resistant unipolar depression","volume":"21","author":"Dold","year":"2017","journal-title":"Int. J. Psychiatry Clin. Pract."},{"issue":"12","key":"10.1016\/j.jad.2023.03.068_bb0120","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/j.euroneuro.2016.10.005","article-title":"Pharmacological treatment strategies in unipolar depression in european tertiary psychiatric treatment centers - a pharmacoepidemiological cross-sectional multicenter study","volume":"26","author":"Dold","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"12","key":"10.1016\/j.jad.2023.03.068_bb0125","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/j.euroneuro.2016.10.005","article-title":"Pharmacological treatment strategies in unipolar depression in european tertiary psychiatric treatment centers \u2013 a pharmacoepidemiological cross-sectional multicenter study","volume":"26","author":"Dold","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2023.03.068_bb0130","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jpsychires.2019.03.008","article-title":"Recall accuracy for the symptoms of a major depressive episode among clinical trial participants","volume":"116","author":"Dunlop","year":"2019","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2023.03.068_bb0135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1034\/j.1600-0447.2000.00003.x","article-title":"Antidepressant drugs: does it matter if they inhibit the reuptake of noradrenaline or serotonin?","volume":"402","author":"Eriksson","year":"2000","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"3","key":"10.1016\/j.jad.2023.03.068_bb0140","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/YIC.0000000000000304","article-title":"A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder","volume":"35","author":"Fagiolini","year":"2020","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.jad.2023.03.068_bb0145","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyw066","article-title":"A neuroscience-based nomenclature (NbN) for psychotropic agents","volume":"19","author":"Frazer","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.jad.2023.03.068_bb0150","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00406-021-01368-3","article-title":"The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in european countries","volume":"272","author":"Fugger","year":"2022","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2023.03.068_bb0160","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jad.2022.06.004","article-title":"The sociodemographic and clinical phenotype of european patients with major depressive disorder undergoing first-line antidepressant treatment with NaSSAs","volume":"312","author":"Fugger","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2023.03.068_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2019.109638","article-title":"Major Depression and Comorbid Diabetes - Findings from the European Group for the Study of Resistant Depression","volume":"94","author":"Fugger","year":"2019","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2023.03.068_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231700","article-title":"Pharmacological treatment of depression: a systematic review comparing clinical practice guideline recommendations","volume":"15","author":"Gabriel","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jad.2023.03.068_bb0175","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2023.03.068_bb0180","first-page":"483","article-title":"Psychopharmaceuticals for treatment of suicidal patients and for suicide prevention","volume":"87","author":"Haussmann","year":"2016","journal-title":"Nervenarzt"},{"key":"10.1016\/j.jad.2023.03.068_bb0185","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jad.2015.03.021","article-title":"Dose equivalents of antidepressants: evidence-based recommendations from randomized controlled trials","volume":"180","author":"Hayasaka","year":"2015","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.jad.2023.03.068_bb0190","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/ijnp\/pyaa068","article-title":"Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II)","volume":"24","author":"Ionescu","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.jad.2023.03.068_bb0195","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1080\/15622975.2020.1836399","article-title":"Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: basic science, evidence-based knowledge and expert guidance","volume":"22","author":"Kasper","year":"2021","journal-title":"World J. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2023.03.068_bb0200","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3109\/15622970701691503","article-title":"Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder","volume":"11","author":"Kasper","year":"2010","journal-title":"World J. Biol. Psychiatry"},{"issue":"9","key":"10.1016\/j.jad.2023.03.068_bb0205","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/0706743716659417","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments","volume":"61","author":"Kennedy","year":"2016","journal-title":"Can. J. Psychiatr."},{"issue":"8","key":"10.1016\/j.jad.2023.03.068_bb0210","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1080\/03007995.2021.1911975","article-title":"Characteristics of patients with major depressive disorder switching SSRI\/SNRI therapy compared with those augmenting with an atypical antipsychotic in a real-world setting","volume":"37","author":"Kern","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"10.1016\/j.jad.2023.03.068_bb0215","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41398-019-0460-3","article-title":"Prognosis and improved outcomes in major depression: a review","volume":"9","author":"Kraus","year":"2019","journal-title":"Transl. Psychiatry"},{"issue":"10","key":"10.1016\/j.jad.2023.03.068_bb0220","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/j.drudis.2019.07.007","article-title":"The influence of ketamine on drug discovery in depression","volume":"24","author":"Kraus","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jad.2023.03.068_bb0225","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fpsyt.2020.00035","article-title":"National Prescription Patterns of antidepressants in the treatment of adults with major depression in the US between 1996 and 2015: a population representative survey based analysis","volume":"11","author":"Luo","year":"2020","journal-title":"Front Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2023.03.068_bb0230","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2710.2009.01050.x","article-title":"Comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials","volume":"35","author":"Machado","year":"2010","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.jad.2023.03.068_bb0235","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jad.2020.02.023","article-title":"The identification, assessment and management of difficult-to-treat depression: an international consensus statement","volume":"267","author":"McAllister-Williams","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2023.03.068_bb0240","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2023.03.068_bb0245","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/YIC.0b013e3282eff7e0","article-title":"Which antidepressants have demonstrated superior efficacy? A review of the evidence","volume":"22","author":"Montgomery","year":"2007","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.jad.2023.03.068_bb0250","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/acps.13097","article-title":"Incidence of suicidal behaviour and violent crime following antidepressant medication: a danish cohort study","volume":"140","author":"Osler","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"issue":"6","key":"10.1016\/j.jad.2023.03.068_bb0255","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/YIC.0000000000000328","article-title":"Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study","volume":"35","author":"Papakostas","year":"2020","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.jad.2023.03.068_bb0260","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.biopsych.2007.03.027","article-title":"Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents","volume":"62","author":"Papakostas","year":"2007","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2023.03.068_bb0265","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/YIC.0000000000000326","article-title":"Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study","volume":"35","author":"Rancans","year":"2020","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.03.068_bb0270","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jad.2019.04.018","article-title":"Psychotropic polypharmacy reconsidered: between-class polypharmacy in the context of multimorbidity in the treatment of depressive disorders","volume":"252","author":"Rhee","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2023.03.068_bb0275","first-page":"1","article-title":"Dose-response relationship in selective serotonin and norepinephrine reuptake inhibitors in the treatment of major depressive disorder: a meta-analysis and network meta-analysis of randomized controlled trials","author":"Rink","year":"2021","journal-title":"Psychother. Psychosom."},{"issue":"3","key":"10.1016\/j.jad.2023.03.068_bb0280","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/JCP.0000000000001400","article-title":"The pitfalls of psychotropic polypharmacy","volume":"41","author":"Rothschild","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.03.068_bb0285","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jad.2020.12.073","article-title":"Time trends in pharmacological treatment of major depressive disorder: results from the AMSP pharmacovigilance program from 2001\u20132017","volume":"281","author":"Seifert","year":"2021","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.jad.2023.03.068_bb0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9758\/cpn.2018.16.1.1","article-title":"The present and future of precision medicine in psychiatry: focus on clinical psychopharmacology of antidepressants","volume":"16","author":"Serretti","year":"2018","journal-title":"Clin. Psychopharmacol. Neurosci."},{"issue":"Suppl. 20","key":"10.1016\/j.jad.2023.03.068_bb0295","first-page":"22","article-title":"The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"issue":"9","key":"10.1016\/j.jad.2023.03.068_bb0300","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1093\/ijnp\/pyy048","article-title":"Suicidal ideation and suicidal behavior as rare adverse events of antidepressant medication: current report from the AMSP multicenter drug safety surveillance project","volume":"21","author":"Stubner","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"12","key":"10.1016\/j.jad.2023.03.068_bb0305","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1177\/0269881120953983","article-title":"Antidepressant responses in direct comparisons of melancholic and non-melancholic depression","volume":"34","author":"Undurraga","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.03.068_bb0310","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jpsychires.2019.01.020","article-title":"Seasonality of antidepressant prescriptions and sick leaves","volume":"111","author":"Winkler","year":"2019","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2023.03.068_bb0315","series-title":"SKID-I, Strukturiertes Klinisches Interview f\u00fcr DSM-IV","author":"Wittchen","year":"1997"},{"issue":"12","key":"10.1016\/j.jad.2023.03.068_bb0320","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/j.euroneuro.2015.08.019","article-title":"A review of the current nomenclature for psychotropic agents and an introduction to the neuroscience-based nomenclature","volume":"25","author":"Zohar","year":"2015","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032723004160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032723004160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T03:58:02Z","timestamp":1759031882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032723004160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":63,"alternative-id":["S0165032723004160"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2023.03.068","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world characteristics of European patients receiving SNRIs as first-line treatment for major depressive disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2023.03.068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}